-
公开(公告)号：EP0885294A2
公开(公告)日：1998-12-23
申请号：EP97907730.0
申请日：1997-02-11
发明人： BAKER, Joffre , CHIEN, Kenneth , KING, Kathleen , PENNICA, Diane , WOOD, William
CPC分类号： C12N5/0606 , A61K35/34 , A61K38/204 , C12N2501/115 , C12N2501/125 , C12N2501/175
摘要： Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. CT-1 is shown to bind to and activate the receptor, LIFRβ. These CT-1 molecules are shown to influence hypertrophic activity, neurological activity, and other activities associated with receptor LIFRβ. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, neurological disorders, and other disorders associated with the LIFRβ.
-
公开(公告)号：EP0755446B1
公开(公告)日：2006-09-13
申请号：EP95921220.0
申请日：1995-04-06
发明人： BAKER, Joffre , CHIEN, Kenneth , KING, Kathleen , PENNICA, Diane , WOOD, William
IPC分类号： C12N15/19 , C12N15/75 , C07K14/52 , C07K16/24 , C12N1/21 , C12N5/16 , G01N33/53 , C12Q1/68 , C12Q1/00
CPC分类号： C12Q1/025 , A01K2217/05 , A61K38/00 , C07K14/52 , G01N33/6872 , G01N2500/00 , Y10S930/14
摘要： Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
-
公开(公告)号：EP0755446A1
公开(公告)日：1997-01-29
申请号：EP95921220.0
申请日：1995-04-06
发明人： BAKER, Joffre , CHIEN, Kenneth , KING, Kathleen , PENNICA, Diane , WOOD, William
CPC分类号： C12Q1/025 , A01K2217/05 , A61K38/00 , C07K14/52 , G01N33/6872 , G01N2500/00 , Y10S930/14
摘要： Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
-
4.发明授权A MUTANT PHOSPHOLAMBAN MOLECULE AND ITS USE IN THE TREATMENT OF CARDIAC DISEASE AND HEART FAILURE 有权突变磷蛋白分子及其用于心脏病和心力衰竭的治疗
公开(公告)号：EP1126866B1
公开(公告)日：2007-02-07
申请号：EP99960187.5
申请日：1999-11-02
发明人： CHIEN, Kenneth , DILLMAN, Wolfgang , MINAMISAWA, Susanne , HE, Huaping , HOSHIJIMA, Masahiko , MEYER, Markus , SCOTT, Christopher , WANG, Yibin , SILVERMAN, Gregg J.
CPC分类号： C07K14/47 , A01K2217/05 , A61K38/1709 , C07K2319/00 , C12N2799/022
-
5.发明公开SEQUENCES UPSTREAM OF THE CARP GENE, VECTORS CONTAINING THEM AND USES THEREOF 审中-公开序列“上游”鲤鱼基因ARE，向量，它们含有，并且使用
公开(公告)号：EP1358208A2
公开(公告)日：2003-11-05
申请号：EP01995724.0
申请日：2001-12-05
IPC分类号： C07K14/47
CPC分类号： C12N15/85 , A01K2217/05 , C07K14/47 , C12N2830/00 , C12N2830/008 , C12N2830/15 , C12N2830/60 , C12N2830/85
摘要： The invention relates to promoter sequences derived from a portion upstream of the coding sequence of the gene for the CARP protein (Cardiac Ankyrin Repeat Protein), and which are capable of controlling the level and the specificity of expression of a transgene in vivo in cardiac muscle cells. The invention thus describes compositions, constructs, vectors and their uses in vivo for the transfer and expression of a nucleic acid in vivo in cardiac muscle cells. The subject of the present invention is also the use of the promoter sequences for generating transgenic animals which constitute models for studying certain cardiac pathologies.
-
6.发明公开A METHOD FOR INHIBITION OF PHOSPHOLAMBAN ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE AND HEART FAILURE 有权突变磷蛋白分子及其用于心脏病和心力衰竭的治疗
公开(公告)号：EP1126866A2
公开(公告)日：2001-08-29
申请号：EP99960187.5
申请日：1999-11-02
发明人： CHIEN, Kenneth , DILLMAN, Wolfgang , MINAMISAWA, Susanne , HE, Huaping , HOSHIJIMA, Masahiko , MEYER, Markus , SCOTT, Christopher , WANG, Yibin , SILVERMAN, Gregg J.
CPC分类号： C07K14/47 , A01K2217/05 , A61K38/1709 , C07K2319/00 , C12N2799/022
摘要： The present invention provides a method for the treatment of heart failure through the use of small peptide complexes and recombinant proteins which function to enhance contractility in failing hearts and reduce blood pressure in individuals with hypertension by inhibiting the interaction between phospholamban and sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) within cardiomyocytes. In addition, a means is provided for the transport of such therapeutic agents into the cytoplasm and nucleus of cardiomyocytes.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.018 秒)
